NEW YORK, Dec. 29, 2016 -- Pomerantz LLP announces that a class action lawsuit has been filed against TerraVia Holdings, Inc. (“TerraVia” or the “Company”)(NASDAQ:TVIA) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-07388, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired TerraVia securities between March 13, 2013 and November 4, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased TerraVia securities during the Class Period, you have until January 17, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
TerraVia creates and sells food, nutrition, and specialty ingredients from algae. Its platform uses microalgae to produce high-value triglyceride oils, proteins, fibers, micronutrients, and other ingredients, including algal flour.
The Company was formerly known as Solazyme, Inc. and changed its name to TerraVia Holdings, Inc. in March 2016. TerraVia Holdings, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) ingestion of TerraVia’s algal flour caused gastrointestinal distress, including nausea and vomiting; (ii) the Company’s algal flour was therefore unlikely to be a competitive product in the market for nutrition foods; (iii) consequently, the Company had overstated the commercial viability of its algal flour; and (iv) as a result of the foregoing, TerraVia’s public statements were materially false and misleading at all relevant times.
On November 7, 2016, Bloomberg published an article entitled “Soylent Thinks It Found What Was Making People Sick: Algae”, stating that an algal flour ingredient provided by TerraVia for use in Rosa Foods, Inc.’s (“Rosa Foods”) flagship meal replacement drink, Soylent, caused consumers to experience gastrointestinal distress, including nausea and vomiting, and that Rosa Foods would be removing the ingredient altogether from its product formulations by early 2017. Despite TerraVia Senior Vice President Mark Brooks’s adamant denial that TerraVia’s algal flour was responsible, Bloomberg further reported that TerraVia had sent a letter in July to a distributor of Honey Stinger, a Colorado energy bar company owned by EN-R-G Foods, LLC, “warning that [TerraVia] had received a ‘modest number of reports’ showing that algal protein can cause ‘gastrointestinal distress,’ according to a copy seen by Bloomberg”—similar ailments to those reported by Soylent consumers.
On this news, TerraVia’s share price fell $0.15, or 8.11%, to close at $1.70 on November 7, 2016, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



